Pregabalin Capsule
Product Images NDC 71335-1788

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1788). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351788)

Label for Pregabalin Capsules USP, 75 mg oral capsules. The label includes the product NDC 71335-1788-01 and indicates a package quantity of 30 capsules. It is labeled for prescription use only and shows the Bryant Ranch Prepack (BRP Pharmaceuticals) logo. Storage instructions specify room temperature 20°-25°C (68°-77°F).*

FDA Label Image

Label (Lbl7133517882)

Label for Pregabalin 75 mg (CV) capsule, an oral human prescription drug by Bryant Ranch Prepack. The label indicates the capsule colors as orange (light peach) and white, includes storage instructions at 20°-25°C (68°-77°F), and safety advice to keep drugs out of reach of children. The NDC 71335-1788 is shown along with lot and barcode details.*

FDA Label Image

Logo (Logo)

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin at doses of 25 mg, 100 mg, and 200 mg taken three times a day against a placebo. The lines show the trend of patient improvement percentages across different levels of pain improvement.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A Kaplan-Meier survival curve graph comparing the estimated percentage of subjects without LTR (likely loss to response) over a 180-day period between Pregabalin and placebo groups. The y-axis represents the estimated percentage of subjects without LTR, and the x-axis shows the number of days. Pregabalin shows a higher percentage without LTR over time compared to placebo.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph comparing the percent of subjects improved over percent improvement from baseline to Week 12 BOCF between Pregabalin and Placebo groups. The x-axis shows percent improved ranging from 0 to 100, and the y-axis shows the percent of subjects improved ranging from 0 to 100. Two lines represent Pregabalin and Placebo, showing higher improvement percentages for Pregabalin.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph comparing percent of subjects improved over time between Pregabalin and placebo groups. The x-axis shows percent improved from baseline to Week 16 BOCF, and the y-axis shows percent of subjects improved. Two lines represent Pregabalin and placebo, with Pregabalin showing higher improvement throughout the period.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph showing the percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Two curves compare Pregabalin 100 mg three times a day and placebo, depicting different levels of patient pain improvement percentages.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph depicting percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. It compares the effects of Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day against a placebo over a range of pain improvement percentages.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. Three treatment groups are compared: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating differences in pain improvement rates among these groups.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph comparing percent improvement in pain from baseline against percent of patients improved, showing data for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar graph presenting responder rates (%) for Study E1 and Study E3 groups. For Study E1, responder rates are shown for placebo, and three dosing groups (150 mg/day, 300 mg/day, 600 mg/day). For Study E3, responder rates are shown for placebo, 600 mg/day, and 750 mg/day groups. Statistically significant differences versus placebo are indicated.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A line graph showing seizure reduction (median % change from baseline) on the y-axis and dose (mg/day) on the x-axis. It compares seizure reductions across four studies with different dosing schedules (BID and TID). Statistical significance (p-values) is indicated for various dose points in the figure.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph comparing percent of patients improved against percent improvement in pain from baseline for Pregabalin at daily doses of 600 mg, 450 mg, and 300 mg, and a placebo. The graph includes four lines showing patient improvement trends across various pain improvement percentages from 0 to 100%.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure diagram of Pregabalin, showing its molecular composition with labeled atoms including nitrogen (NH2), oxygen (O), carbon (C), and hydrogen (H). The diagram depicts the 3D configuration with bonds and stereochemistry indications.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.